Balchem Q2 Earnings: Record Sales and a Broad-Based Beat Across All Segments
BCPC sits 17% above its 52-week low of $139.17.
Summary
Balchem posted record Q2 2026 results, with sales of $284M (+11% YoY) and adjusted EPS of $1.49, beating consensus. All three segments grew, and aggressive share buybacks continued.
Key Events · Earnings and Guidance · BCPC
-
Record Q2 Sales and Earnings
New quarterly records were set as net sales reached $284.0M (+11.2% YoY) and GAAP net earnings climbed to $44.6M (+16.6% YoY). Adjusted EBITDA also hit a high of $77.9M (+12.6% YoY).
-
Broad-Based Segment Growth
All three segments contributed to the top line: Human Nutrition & Health rose 10.0% to $176.9M, Animal Nutrition & Health jumped 15.0% to $64.5M, and Specialty Products grew 8.9% to $40.5M.
-
Earnings Beat Consensus
Adjusted EPS of $1.49 surpassed the prior-year quarter's $1.27 and exceeded the Reuters-reported consensus of $268.5M in sales.
-
Aggressive Share Repurchases
Reflecting a balanced capital allocation strategy, $29M of common stock was repurchased in Q2, bringing the trailing twelve-month total to $114M.
Analysis · BCPC · Industrial Applications And Services
A clean beat in Q2 2026 underscores Balchem's momentum, with sales surging 11% to $284M against a $268.5M consensus and adjusted EPS of $1.49 topping estimates. Growth was broad-based—all three segments expanded, led by Animal Nutrition & Health at +15%. The quarter also saw $29M in stock repurchases, bringing the trailing twelve-month total to $114M, while the recently upsized $650M credit facility was reiterated. These results build on the strength noted last quarter and support the premium valuation.
At the time of this filing, BCPC was trading at $163.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $139.17 to $183.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.